205 related articles for article (PubMed ID: 33162531)
21. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
22. Breaking the invulnerability of cancer stem cells: two-step strategy to kill the stem-like cell subpopulation of multiple myeloma.
Morgenroth A; Vogg AT; Zlatopolskiy BD; Siluschek M; Oedekoven C; Mottaghy FM
Mol Cancer Ther; 2014 Jan; 13(1):144-53. PubMed ID: 24174494
[TBL] [Abstract][Full Text] [Related]
23. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
24. The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.
Benaniba L; Tessoulin B; Trudel S; Pellat-Deceunynck C; Amiot M; Minvielle S; Gourraud PA; de Visme S; Maisonneuve H; Lok A; Le Gouill S; Moreau P; Touzeau C
BMC Cancer; 2019 Aug; 19(1):855. PubMed ID: 31464608
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents.
Kim KH; Cheong HJ; Lee MY; Lee N; Lee KT; Park SK; Won JH
Anticancer Res; 2019 Jan; 39(1):127-133. PubMed ID: 30591449
[TBL] [Abstract][Full Text] [Related]
26. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
27. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.
Bishop RT; Miller AK; Froid M; Nerlakanti N; Li T; Frieling JS; Nasr MM; Nyman KJ; Sudalagunta PR; Canevarolo RR; Silva AS; Shain KH; Lynch CC; Basanta D
Nat Commun; 2024 Mar; 15(1):2458. PubMed ID: 38503736
[TBL] [Abstract][Full Text] [Related]
28. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.
Mondello P; Cuzzocrea S; Navarra M; Mian M
Oncotarget; 2017 Mar; 8(12):20394-20409. PubMed ID: 28099912
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.
Eun K; Ham SW; Kim H
BMB Rep; 2017 Mar; 50(3):117-125. PubMed ID: 27998397
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
32. Novel therapeutic targets in multiple myeloma.
Davies FE; Anderson KC
Eur J Haematol; 2000 Jun; 64(6):359-67. PubMed ID: 10901589
[TBL] [Abstract][Full Text] [Related]
33. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
Gooding S; Edwards CM
Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
[TBL] [Abstract][Full Text] [Related]
34. Myeloma Propagating Cells, Drug Resistance and Relapse.
Karadimitris A; Chaidos A; Caputo V; Goudevenou K; Ponnusamy K; Xiao X
Stem Cells; 2015 Nov; 33(11):3205-11. PubMed ID: 26302895
[TBL] [Abstract][Full Text] [Related]
35. The next generation of novel therapies for the management of relapsed multiple myeloma.
Gonsalves WI; Milani P; Derudas D; Buadi FK
Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
[TBL] [Abstract][Full Text] [Related]
36. Where we were, where we are, where we are going: progress in multiple myeloma.
Bergsagel PL
Am Soc Clin Oncol Educ Book; 2014; ():199-203. PubMed ID: 24857077
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic strategies to enhance immune response induced by multiple myeloma cells.
Liu Z; Yang C; Liu X; Xu X; Zhao X; Fu R
Front Immunol; 2023; 14():1169541. PubMed ID: 37275861
[TBL] [Abstract][Full Text] [Related]
38. Advances in the biology and treatment of multiple myeloma.
Varterasian ML
Curr Opin Oncol; 1999 Jan; 11(1):3-8. PubMed ID: 9914870
[TBL] [Abstract][Full Text] [Related]
39. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.
Schürch CM; Rasche L; Frauenfeld L; Weinhold N; Fend F
Virchows Arch; 2020 Mar; 476(3):337-351. PubMed ID: 31848687
[TBL] [Abstract][Full Text] [Related]
40. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
